Search results

NICE is unable to make a recommendation on glasdegib with chemotherapy for untreated acute myeloid leukaemia because Pfizer did not provide an evidence

Type

Technology appraisal guidance

Published

02 September 2020

NICE is unable to make a recommendation about the use in the NHS of eculizumab (Soliris) for treating relapsing neuromyelitis optica because Alexion Pharma UK

Type

Technology appraisal guidance

Published

02 September 2020

Evidence-based recommendations on avelumab (Bavencio) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults

Type

Technology appraisal guidance

Published

02 September 2020

Evidence-based recommendations on brentuximab vedotin (Adcetris) with cyclophosphamide, doxorubicin and prednisone for untreated systemic anaplastic large cell

Type

Technology appraisal guidance

Published

12 August 2020

Evidence-based recommendations on gilteritinib (Xospata) for relapsed or refractory FLT3-mutation-positive acute myeloid leukaemia in adults

Type

Technology appraisal guidance

Published

12 August 2020

Evidence-based recommendations on entrectinib (Rozlytrek) for ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults who have not had ROS1

Type

Technology appraisal guidance

Published

12 August 2020

Evidence-based recommendations on entrectinib (Rozlytrek) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and

Type

Technology appraisal guidance

Published

12 August 2020

Evidence-based recommendations on deep brain stimulation for refractory epilepsy in adults. This involves implanting an electrical stimulator in the brain

Type

Interventional procedures guidance

Published

12 August 2020

Evidence-based recommendations on vagus nerve stimulation for treatment-resistant depression in adults. This involves implanting an electrical stimulator under

Type

Interventional procedures guidance

Published

12 August 2020

Evidence-based recommendations on treosulfan (Trecondi) with fludarabine for conditioning treatment before allogeneic haematopoietic stem cell transplant for

Type

Technology appraisal guidance

Published

05 August 2020

Evidence-based recommendations on transcranial magnetic stimulation for obsessive-compulsive disorder in adults. This involves pulsing electromagnetic energy

Type

Interventional procedures guidance

Published

05 August 2020

Evidence-based recommendations on electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney

Type

Interventional procedures guidance

Published

05 August 2020

Evidence-based recommendations on artificial iris insertion for acquired aniridia. This involves inserting an artificial iris into the eye

Type

Interventional procedures guidance

Published

22 July 2020

Evidence-based recommendations on artificial iris insertion for congenital aniridia. This involves inserting an artificial iris into the eye

Type

Interventional procedures guidance

Published

22 July 2020

Evidence-based recommendations on atezolizumab (Tecentriq) for untreated extensive-stage small-cell lung cancer in adults

Type

Technology appraisal guidance

Published

01 July 2020

Evidence-based recommendations on atezolizumab (Tecentriq) with nab-paclitaxel for triple-negative, unresectable, PD-L1-positive, locally advanced or metastatic

Type

Technology appraisal guidance

Published

01 July 2020

NICE is unable to make a recommendation on daratumumab (Darzalex) with lenalidomide and dexamethasone for untreated multiple myeloma, because Janssen did not

Type

Technology appraisal guidance

Published

30 June 2020

NICE is unable to make a recommendation on ramucirumab (Cyramza) with erlotinib for untreated epidermal growth factor receptor (EGFR)-positive metastatic non

Type

Technology appraisal guidance

Published

30 June 2020

NICE is unable to make a recommendation on eculizumab (Soliris) for treating refractory myasthenia gravis because Alexion Pharma UK did not provide an evidence

Type

Technology appraisal guidance

Published

30 June 2020

NICE is unable to make a recommendation about the use in the NHS of ranibizumab (Lucentis) for treating diabetic retinopathy because Novartis did not provide an

Type

Technology appraisal guidance

Published

30 June 2020

Evidence-based recommendations on avatrombopag (Doptelet) for treating severe thrombocytopenia in adults with chronic liver disease needing a planned invasive

Type

Technology appraisal guidance

Published

24 June 2020

Evidence-based recommendations on intravascular lithotripsy for calcified coronary arteries during percutaneous coronary intervention in adults. This involves

Type

Interventional procedures guidance

Published

24 June 2020

Evidence-based recommendations on ustekinumab (Stelara) for treating moderately to severely active ulcerative colitis in adults

Type

Technology appraisal guidance

Published

17 June 2020

Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for human epidermal growth factor receptor 2 (HER2)-positive early breast cancer in adults who

Type

Technology appraisal guidance

Published

10 June 2020

Evidence-based recommendations on fremanezumab (Ajovy) for preventing chronic migraine in adults

Type

Technology appraisal guidance

Published

03 June 2020

Evidence-based recommendations on larotrectinib (Vitrakvi) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and

Type

Technology appraisal guidance

Published

27 May 2020

Evidence-based recommendations on lorlatinib (Lorviqua) for previously treated ALK-positive advanced non-small-cell lung cancer in adults

Type

Technology appraisal guidance

Published

13 May 2020

Evidence-based recommendations on obinutuzumab (Gazyvaro) with bendamustine for follicular lymphoma that has not responded or has progressed up to 6 months

Type

Technology appraisal guidance

Published

13 May 2020

Evidence-based recommendations on lenalidomide (Revlimid) with rituximab for previously treated follicular lymphoma (grade 1 to 3A) in adults

Type

Technology appraisal guidance

Published

07 April 2020

Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing–remitting multiple sclerosis in adults.

Type

Technology appraisal guidance

Last updated

17 March 2020

NICE is unable to make a recommendation on recombinant human parathyroid hormone for treating hypoparathyroidism because Shire Pharmaceuticals

Type

Technology appraisal guidance

Published

04 March 2020

Evidence-based recommendations on selective internal radiation therapy for unresectable colorectal metastases in the liver in adults. This involves injecting

Type

Interventional procedures guidance

Published

04 March 2020

Evidence-based recommendations on cyanoacrylate glue occlusion for varicose veins. This involves injecting medical glue (cyanoacrylate) into a vein to close it

Type

Interventional procedures guidance

Published

04 March 2020

Evidence-based recommendations on MRI-guided laser interstitial thermal therapy for drug-resistant epilepsy in adults and children. This involves inserting a

Type

Interventional procedures guidance

Published

04 March 2020

Evidence-based recommendations on bilateral cervicosacropexy (CESA) or vaginosacropexy (VASA) using mesh for pelvic organ prolapse in adults

Type

Interventional procedures guidance

Published

04 March 2020

This guideline sets out an antimicrobial prescribing strategy for adults, young people and children aged 72 hours and over with impetigo. It aims to optimise antibiotic use and reduce antibiotic resistance.

Type

Antimicrobial prescribing guideline

Published

26 February 2020

Evidence-based recommendations on peginterferon beta-1a (Plegridy) for treating relapsing–remitting multiple sclerosis in adults

Type

Technology appraisal guidance

Published

19 February 2020

Evidence based recommendations on patiromer (Veltassa) for treating hyperkalaemia in adults

Type

Technology appraisal guidance

Published

13 February 2020

Evidence-based recommendations on sotagliflozin with insulin for treating type 1 diabetes in adults with a body mass index (BMI) of at least 27 kg/m2

Type

Technology appraisal guidance

Published

12 February 2020

Evidence-based recommendations on dapagliflozin (Forxiga) with insulin for treating type 1 diabetes not controlled by insulin therapy alone in adults with a

Type

Technology appraisal guidance

Last updated

12 February 2020

This guideline sets out an antimicrobial prescribing strategy for adults with leg ulcer infection. It aims to optimise antibiotic use and reduce antibiotic resistance.

Type

Antimicrobial prescribing guideline

Published

11 February 2020

Evidence-based recommendations on fetoscopic prenatal repair of open neural tube defects in the fetus

Type

Interventional procedures guidance

Published

29 January 2020

Evidence-based recommendations on open prenatal repair of open neural tube defects in the fetus

Type

Interventional procedures guidance

Published

29 January 2020

Evidence-based recommendations on reducing the risk of Creutzfeldt–Jakob disease (CJD) transmission from surgical instruments used for interventional procedures

Type

Interventional procedures guidance

Published

22 January 2020

This guideline covers support for adults (aged 18 and over) who provide unpaid care for anyone aged 16 or over with health or social care needs. It aims to improve the lives of carers by helping health and social care practitioners identify people who are caring for someone and give them the right information and support. It covers carers’ assessments, practical, emotional and social support and training, and support for carers providing end of life care.

Type

NICE guideline

Published

22 January 2020

Evidence-based recommendations on olaparib (Lynparza) for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal

Type

Technology appraisal guidance

Published

15 January 2020

NICE is unable to make a recommendation about the use in the NHS of atezolizumab (Tecentriq) with carboplatin and nab-paclitaxel for untreated advanced NSCLC

Type

Technology appraisal guidance

Published

15 January 2020

Evidence-based recommendations on palbociclib (Ibrance) with fulvestrant for hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer

Type

Technology appraisal guidance

Published

15 January 2020

Evidence-based recommendations on lusutrombopag (Mulpleo) for severe thrombocytopenia in adults with chronic liver disease needing a planned invasive procedure

Type

Technology appraisal guidance

Published

08 January 2020

Evidence-based recommendations on cladribine (Mavenclad) for relapsing–remitting multiple sclerosis (RRMS) in adults

Type

Technology appraisal guidance

Published

19 December 2019